Genentech

Genentech, Inc. has promoted four vice presidents to senior vice president and has appointed a new vice president. The four new senior vice presidents include: Markus Gemuend, senior vice president, biochemical manufacturing; Sean A. Johnston, senior vice president and general counsel; Timothy L. Moore, senior vice president, global supply chain; and John Orwin, senior vice president, sales and marketing, BioOncology. Also Christopher Horan was promoted to vice president, planning, distribution and logistics (formerly known as Supply Chain Management).

Mr. Gemuend will report to Patrick Y. Yang, Ph.D., executive vice president, product operations. Mr. Gemuend is responsible for all of the company’s biochemical manufacturing of bulk product. He joined the company in 2004 as vice president, manufacturing collaborations and contract manufacturing. Prior to joining Genentech, he spent 16 years at Lonza Group, Ltd., where he served as chief executive officer from 2002 to 2004 and held several other leadership roles, including senior vice president and sector head for Lonza Biologics as well as vice president for Exclusive Synthesis U.S.

Mr. Johnston will report to Stephen G. Juelsgaard, executive vice president, secretary and chief compliance officer. Mr. Johnston is responsible for Genentech’s corporate law and intellectual property groups. He joined the company in 1990 as patent counsel and was promoted to vice president, intellectual property in 1998. Prior to joining the company, Mr. Johnston was law clerk to Judge Wm. Matthew Byrne, Jr. in the U.S. District Court, Central District of CA in Los Angeles. Before that, he was a research scientist at International Genetic Engineering, Inc./Xoma Corp.

Mr. Moore will report to Patrick Y. Yang, Ph.D., executive vice president, product operations. Mr. Moore is responsible for managing the entire drug production life cycle. In addition to managing the supply chain, he will be responsible for manufacturing collaborations and fill/finish operations. He joined the company in 2004 as vice president, corporate engineering and was named vice president, South San Francisco manufacturing in December 2004. Prior to joining the company, he served as vice president, operations at ZLB Behring (formerly Aventis Behring) and managed aseptic/biological manufacturing operations.

Mr. Orwin will report to Ian T. Clark, executive vice president, commercial operations. Mr. Orwin continues to lead the sales and marketing activities for the BioOncology commercial team, which includes the Avastin, HER Family Products, and Rituxan businesses. He joined the company in 2005 as vice president, HER Family product sales and marketing, and was promoted to vice president, sales and marketing, BioOncology, that same year. Prior to joining the company, he served as the franchise vice president, oncology of the Tibotec Therapeutics group within Johnson & Johnson’s Ortho Biotech division.

Mr. Horan will report to Timothy L. Moore, senior vice president, global supply chain. Mr. Horan is responsible for product and materials planning for the company’s entire supply chain. He joined the company in 2004 as senior director, operational excellence and most recently held the role of senior director, supply chain operations, planning and logistics. Prior to Genentech, he held several leadership positions within Merck & Co. Inc. in international manufacturing and the development of Merck’s Global Operational Excellence organization.